Paredes de la Fuente, R.; Sucre, S.; Ponce, C.; Rattani, A.A.A.; Peters, M.L.B.
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers 2024, 16, 2734.
https://doi.org/10.3390/cancers16152734
AMA Style
Paredes de la Fuente R, Sucre S, Ponce C, Rattani AAA, Peters MLB.
Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers. 2024; 16(15):2734.
https://doi.org/10.3390/cancers16152734
Chicago/Turabian Style
Paredes de la Fuente, Rodrigo, Santiago Sucre, Cristina Ponce, Ahmed Anwer Ali Rattani, and Mary Linton B. Peters.
2024. "Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel" Cancers 16, no. 15: 2734.
https://doi.org/10.3390/cancers16152734
APA Style
Paredes de la Fuente, R., Sucre, S., Ponce, C., Rattani, A. A. A., & Peters, M. L. B.
(2024). Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. Cancers, 16(15), 2734.
https://doi.org/10.3390/cancers16152734
